Koninklijke Philips (NYSE:PHG) Rating Lowered to "Hold" at Wall Street Zen

Koninklijke Philips (NYSE:PHG - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Friday.

Several other research firms have also issued reports on PHG. Sanford C. Bernstein upgraded Koninklijke Philips from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 18th. BNP Paribas upgraded shares of Koninklijke Philips from a "neutral" rating to an "outperform" rating in a report on Tuesday, February 25th. Finally, UBS Group upgraded Koninklijke Philips from a "neutral" rating to a "buy" rating in a report on Thursday, February 20th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy".

Koninklijke Philips Price Performance

Shares of NYSE:PHG traded down $0.24 during midday trading on Friday, reaching $22.81. The company's stock had a trading volume of 1,007,791 shares, compared to its average volume of 834,684. The business's fifty day simple moving average is $23.97 and its 200-day simple moving average is $25.50. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.23 and a quick ratio of 0.74. Koninklijke Philips has a fifty-two week low of $21.48 and a fifty-two week high of $32.91. The company has a market capitalization of $21.44 billion, a P/E ratio of -27.15, a P/E/G ratio of 0.82 and a beta of 0.81.

Koninklijke Philips (NYSE:PHG - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The technology company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.13. Koninklijke Philips had a positive return on equity of 10.85% and a negative net margin of 3.88%. The firm had revenue of $4.31 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the company earned $0.21 EPS. The business's quarterly revenue was down 1.0% compared to the same quarter last year. As a group, equities research analysts expect that Koninklijke Philips will post 1.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Fiduciary Management Inc. WI lifted its position in Koninklijke Philips by 21.7% in the 1st quarter. Fiduciary Management Inc. WI now owns 7,515,737 shares of the technology company's stock valued at $190,900,000 after acquiring an additional 1,339,055 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Koninklijke Philips by 2.5% during the first quarter. Dimensional Fund Advisors LP now owns 4,396,095 shares of the technology company's stock worth $111,662,000 after buying an additional 106,044 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Koninklijke Philips by 87.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 2,222,192 shares of the technology company's stock worth $56,266,000 after buying an additional 1,038,321 shares in the last quarter. Northern Trust Corp raised its position in Koninklijke Philips by 5.1% in the 1st quarter. Northern Trust Corp now owns 1,690,402 shares of the technology company's stock valued at $42,936,000 after buying an additional 81,653 shares during the last quarter. Finally, Causeway Capital Management LLC raised its position in Koninklijke Philips by 24.0% in the 4th quarter. Causeway Capital Management LLC now owns 1,566,850 shares of the technology company's stock valued at $39,673,000 after buying an additional 303,428 shares during the last quarter. Institutional investors and hedge funds own 13.67% of the company's stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.